PROPHYLACTIC OR PRE-EMPTIVE USE OF TYROSINE KINASE INHIBITORS POST-ALLOGENEIC STEM CELL TRANSPLANTATION IN BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A SUBANALYSIS OF GITMO PH-POSITIVE ALL STUDY.

EHA Library, Anna Candoni, 324648

NARSOPLIMAB (OMS721) TREATMENT CONTRIBUTES TO IMPROVEMENTS IN ORGAN FUNCTION IN ADULT PATIENTS WITH HIGH-RISK TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

EHA Library, Miguel-Angel Perales, 324649

FLUDARABINE AND TBI 8 GY VERSUS FLUDARABINE AND TREOSULFAN CONDITIONING IN PATIENTS WITH AML IN FIRST COMPLETE REMISSION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

EHA Library, Gesine Bug, 324650

CMML PATIENTS UNDERGOING ALLOGENEIC HCT HAVE INFERIOR SURVIVAL OUTCOMES IN COMPARISON WITH MDS PATIENTS DUE TO A SIGNIFICANTLY HIGHER RELAPSE RATE. A REGISTRY STUDY OF THE EBMT-CMWP

EHA Library, Alicia Rovó, 324651

AUTOLOGOUS OR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PERIPHERAL T-CELL LYMPHOMA-NOT OTHERWISE SPECIFIED AND ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA FAILING FIRST-LINE THERAPY

EHA Library, Kazuaki Kameda, 324652

INFLAMMATORY-RESPONDING MESENCHYMAL STROMAL CELLS MODULATE THE DYNAMIC BONE MARROW MICROENVIRONMENT RESPONSE TO STRESS

EHA Library, Shubhankar Sood, 324653

DORMANCY PROTECTS FUNCTIONAL POTENTIAL OF HEMATOPOIETIC STEM CELLS UNDER HOMEOSTATIC AND STRESS CONDITIONS

EHA Library, Ana-Matea Mikecin Drazic, 324654

MICROENVIRONMENTAL SFRP1 REGULATES REPOPULATING ACTIVITY OF HEMATOPOIETIC STEM CELLS VIA PP2A-MEDIATED REGULATION OF CTNNB1/EP300

EHA Library, Robert A.J. Oostendorp, 324655

LOW-CYTOKINE ENVIRONMENT DETERMINES THE OUTCOME OF EMBRYONIC HEMATOPOIESIS IN MOUSE FETAL LIVER

EHA Library, Francisca Soares-Da-Silva, 324656

REDUCED LEVELS OF THROMBOPOIETIN CONTRIBUTE TO IMPAIRED HEMATOPOIETIC STEM CELL FUNCTION AND DEFECTIVE MEGAKARYOPOIESIS IN ΒETA-THALASSEMIA

EHA Library, Annamaria Aprile, 324657

ADCLEC.SYN1, A COMBINATORIAL CAR PLATFORM FOR AML

EHA Library, Sascha Haubner, 324658

PRECLINICAL DATA SUPPORTING THE INITIATION OF THE EDIT-301 PHASE I RUBY CLINICAL TRIAL FOR THE POTENTIAL TREATMENT OF SICKLE CELL DISEASE

EHA Library, Edouard De Dreuzy, 324659

LAG-3, TIM-3 OR 2B4 DISRUPTION DIFFERENTIALLY REGULATE THE ANTI-TUMOR RESPONSE OF TCR GENE EDITED HUMAN MEMORY STEM T CELLS

EHA Library, Beatrice Claudia Cianciotti, 324660

ENGINEERED REGULATORY T CELLS USING ORTHOGONAL IL-2 CYTOKINE-RECEPTOR COMPLEXES PREVENT ACUTE GRAFT-VERSUS-HOST DISEASE.

EHA Library, Teresa Ramos, 324661

CORD-BLOOD-DERIVED T AND NATURAL KILLER CELLS ENGINEERED VIA THE PIGGYBAC TRANSPOSON SYSTEM TO EXPRESS A LIGAND-BASED CAR TARGETING THE CD116/CD131 COMPLEX

EHA Library, Hirokazu Morokawa, 324662

POLATUZUMAB VEDODTIN VS. CAR-T CELL FOR PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA - A PROPENSITY SCORE MATCHED ANALYSIS

EHA Library, Irit Avivi, 324663

26 WEEK EFFICACY AND SAFETY OF ETRANACOGENE DEZAPARVOVEC (AAV5-PADUA HFIX VARIANT; AMT-061) IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B TREATED IN THE PHASE 3 HOPE-B CLINICAL TRIAL

EHA Library, Wolfgang Miesbach, 324664

BETIBEGLOGENE AUTOTEMCEL GENE THERAPY FOR THE TREATMENT OF TRANSFUSION-DEPENDENT Β-THALASSEMIA: UPDATED LONG-TERM EFFICACY AND SAFETY RESULTS

EHA Library, Evangelia Yannaki, 324665

RETROVIRAL GENE THERAPY FOR THE TREATMENT OF ADA-SCID: LONG-TERM FOLLOW UP AND FIRST CASE OF T-CELL ACUTE LEUKAEMIA DUE TO INSERTIONAL MUTAGENESIS

EHA Library, Maria Pia Cicalese, 324666

A PHASE I-IIA STUDY OF GENETICALLY MODIFIED TIE-2 EXPRESSING MONOCYTES IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (TEM-GBM STUDY)

EHA Library, Fabio Ciceri, 324667

SAFETY AND EFFICACY OF VOXELOTOR IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE AGED 4-11 YEARS

EHA Library, Clark Brown, 324668

COMPLETE RESOLUTION OF SEVERE VASO-OCCLUSIVE EVENTS AND IMPROVED PATHOPHYSIOLOGY WITH LENTIGLOBIN GENE THERAPY IN SICKLE CELL DISEASE (SCD): ONGOING PHASE 1/2 HGB-206 GROUP C STUDY

EHA Library, Janet L. Kwiatkowski, 324669

ISCHEMIC WHITE MATTER LESIONS ARE ASSOCIATED WITH COGNITIVE DYSFUNCTION IN ADULTS WITH SICKLE CELL DISEASE

EHA Library, Florence Blais, 324670

THE SAFETY, PHARMACOKINETICS & PHARMACODYNAMIC EFFECTS OF IMR-687, A HIGHLY-SELECTIVE PDE9 INHIBITOR, IN ADULTS WITH SICKLE CELL DISEASE: PHASE-2A PLACEBO-CONTROLLED & OPEN-LABEL EXTENSION STUDIES

EHA Library, Biree Andemariam, 324671

DIFFERENTIAL ENDOTHELIAL VCAM1 EXPRESSION AND IMPLICATIONS FOR SICKLE CELL ANEMIA VASCULOPATHY

EHA Library, Marisa Silva, 324672

MIR-451 FUNCTION ON ULK1-MEDIATED AUTOPHAGY OF FREE ΑLPHA-GLOBIN IN ΒETA-THALASSEMIA

EHA Library, Christophe Lechauve, 324673

BETIBEGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA: UPDATED RESULTS FROM HGB-207 (NORTHSTAR-2) AND HGB-212 (NORTHSTAR-3)

EHA Library, Franco Locatelli, 324674

RESULTS FROM A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

EHA Library, Kevin H.M. Kuo, 324675

INHIBITION OF FIBROBLAST GROWTH FACTOR-23 (FGF-23) AS A NOVEL STRATEGY TO TARGET BONE AND HEMATOPOIETIC STEM CELL NICHE DEFECTS IN ΒETA-THALASSEMIA

EHA Library, Annamaria Aprile, 324676

TGF-BETA SIGNALING CONTROLS THE LINEAGE CELL FATE OF HEMATOPOIETIC STEM CELLS TOWARDS ERYTHROID BRANCHING IN BETA-THALASSEMIA

EHA Library, Maria Rosa Lidonnici, 324677

ACTIVATE: A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MITAPIVAT IN ADULTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED

EHA Library, Hanny Al-Samkari, 324678

ACTIVATE-T: A PHASE 3, OPEN-LABEL, MULTICENTER STUDY OF MITAPIVAT IN ADULTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED

EHA Library, Andreas Glenthøj, 324679

IDENTIFICATION OF A NOVEL GENE CAUSING AN AUTOSOMAL RECESSIVE FORM OF CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE III

EHA Library, Gonzalo Hernández, 324680

ESTABLISHMENT AND PHENOTYPING OF VIABLE MOUSE MODELS OF X-LINKED SIDEROBLASTIC ANEMIA AND PROTOPORPHYRIA USING CRISPR-CAS9 EDITING

EHA Library, Sarah Ducamp, 324681

METABOLIC FINGERPRINT IN HEREDITARY SPHEROCYTOSIS CORRELATES WITH RED BLOOD CELL CHARACTERISTICS AND CLINICAL SEVERITY

EHA Library, Birgit Van Dooijeweert, 324682

HEPATOCYTES INSTRUCT LIVER SINUSOIDAL ENDOTHELIAL CELLS TO INDUCE BMP6 IN RESPONSE TO IRON

EHA Library, Silvia Colucci, 324683

NEW INSIGHTS INTO PATHOGENIC MECHANISMS OF HEPATIC IRON METABOLISM DUE TO PIEZO1 GAIN OF FUNCTION VARIANTS.

EHA Library, Immacolata Andolfo, 324684

ANEMIA OF CHRONIC KIDNEY DISEASE IS PREVENTED THROUGH TRANSFERRIN RECEPTOR 2 INHIBITION

EHA Library, Violante Olivari, 324685

LOSS OF ERYTHROBLASTS IN ACUTE MYELOID LEUKEMIA CAUSES IRON REDISTRIBUTION WITH CLINICAL IMPLICATIONS

EHA Library, Delfim Duarte, 324686

HEPCIDIN IS A MARKER OF COVID-19 SEVERITY AND MORTALITY IN A COHORT OF HOSPITALIZED ITALIAN PATIENTS

EHA Library, Laura Silvestri, 324687

DEVELOPMENT OF NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 IN HEALTHY SANITARY WORKERS AND OCTOGENARIANS POST-BNT162B2 MRNA COVID-19 VACCINE: FIRST RESULTS OF A PROSPECTIVE TRIAL IN 366 INDIVIDUALS

EHA Library, evangelos Terpos, 324688

EHA GUIDELINE: ANTIFUNGAL PROPHYLAXIS IN ACUTE MYELOID LEUKEMIA TREATED WITH NOVEL AGENTS

EHA Library, Jannik Stemler, 324689

RATIONAL: A RANDOMISED CONTROLLED FEASIBILITY TRIAL COMPARING PROPHYLACTIC IMMUNOGLOBULIN WITH ANTIBIOTICS IN PATIENTS WITH ACQUIRED HYPOGAMMAGLOBULINEMIA SECONDARY TO HAEMATOLOGICAL MALIGNANCIES

EHA Library, Zoe McQuilten, 324690

BASELINE CT THORAX AND RISK OF INVASIVE FUNGAL DISEASE IN ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Varun Mehra, 324691

EARLY INFECTIONS FOLLOWING COMMERCIAL ANTI-CD19 CAR-T CELLS INFIRM POPULATION – A SINGLE CENTER RETROSPECTIVE STUDY

EHA Library, Ofrat Beyar-Katz, 324692

SAFETY AND EFFICACY OF THE BNT162B2 MRNA COVID-19 VACCINE IN PATIENTS AFTER ALLOGENEIC HCT AND CD19-BASED CAR-T THERAPY – A SINGLE CENTER PROSPECTIVE COHORT STUDY

EHA Library, Ron Ram, 324693

OUTCOMES IN PATIENTS WITH ACUTE LEUKAEMIA AND COVID-19: RESULTS OF SUBGROUP ANALYSIS OF CHRONOS19 REGISTRY

EHA Library, Olga Aleshina (Gavrilina), 324694

KINETICS OF ANTIBODIES AGAINST SARS-COV-2 IN CONVALESCENT PLASMA DONORS AFTER EIGHT MONTHS FROM COVID-19: PERSISTENCE OF SPIKE ANTIBODIES BUT LOSS OF NEUTRALIZING ANTIBODIES IN 24% OF DONORS

EHA Library, evangelos Terpos, 324695

COVID-19 AMONG PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A NATIONAL ISRAELI RETROSPECTIVE ANALYSIS

EHA Library, Ilana Levy, 324696

SEROCONVERSION AND LONGEVITY OF ANTI SARS-COV-2 ANTIBODIES IN ONCO-HEMATOLOGIC PATIENTS WHO EXPERIENCED SARS-COV-2 INFECTION.

EHA Library, Anna Candoni, 324697

SUTIMLIMAB, A TARGETED COMPLEMENT C1S INHIBITOR, IMPROVES QUALITY OF LIFE (QOL) IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FROM THE RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 CADENZA STUDY

EHA Library, Alexander Röth, 324698

C1S-TARGETED INHIBITION OF CLASSICAL COMPLEMENT PATHWAY BY SUTIMLIMAB IN COLD AGGLUTININ DISEASE (CAD): EFFICACY AND SAFETY RESULTS FROM THE RANDOMIZED, PLACEBO (PBO)-CONTROLLED PHASE 3 CADENZA STUDY

EHA Library, Alexander Röth, 324699

HEMOSTATIC CHARACTERIZATION OF POST-COVID-19 CONVALESCENT PLASMA DONORS: THE BERGAMO EXPERIENCE

EHA Library, Carmen Tartari, 324700

DESCRIPTION OF THE INFLAMMATORY PROFILE WITH 45 CYTOKINES ACCORDING TO ABO BLOOD GROUP IN COVID-19 AND ITS IMPLICATIONS ON SEVERITY AND MORTALITY.

EHA Library, Alvaro Tamayo-Velasco, 324701

LARGE-SCALE PRODUCTION OF CULTURED ERYTHROCYTES USING BIOREACTORS

EHA Library, Marie-José Claessen, 324702

A RESERVOIR OF RITUXIMAB-RESISTANT SPLENIC MEMORY B CELLS CONTRIBUTES TO RELAPSES AFTER B-CELL DEPLETION THERAPY

EHA Library, Etienne Crickx, 324703

LONG-TERM SURVIVAL IN PATIENTS WITH PRIMARY AND SECONDARY IMMUNE THROMBOCYTOPENIA - A NATIONWIDE POPULATION-BASED COHORT STUDY

EHA Library, Nikolaj Mannering, 324704

FEATURES OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IDENTIFIED THROUGH SINGLE-CELL RNA SEQUENCING IN IMMUNE THROMBOCYTOPENIA

EHA Library, Yan Liu, 324705

HIGH LEVEL OF ESTRADIOL INDUCES MEGAKARYOCYTE APOPTOSIS AND IMPAIRS PROPLATELET FORMATION VIA MST1-FOXO1 AXIS DURING PREGNANCY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA

EHA Library, Qi Chen, 324706

PHASE I/II UPDATED SAFETY AND EFFICACY RESULTS OF ORAL BRUTON TYROSINE KINASE (BTK) INHIBITOR RILZABRUTINIB IN RELAPSED/REFRACTORY IMMUNE THROMBOCYTOPENIA (ITP)

EHA Library, David Kuter, 324707

CHIP-ASSOCIATED MUTANT ASXL1 ACTIVATES INNATE IMMUNE PATHWAY IN MYELOID CELLS AND PROMOTES ATHEROSCLEROSIS IN MICE

EHA Library, Naru Sato, 324708

RAVULIZUMAB REDUCES THE RISK OF THROMBOSIS IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND HIGH DISEASE ACTIVITY: 2-YEAR DATA FROM A PHASE 3, OPEN-LABEL STUDY

EHA Library, Regis Peffault De La Tour, 324709

HALF-LIFE PROLONGATION OF VON WILLEBRAND FACTOR: A NEW THERAPEUTIC STRATEGY FOR HAEMOPHILIA A AND VON WILLEBRAND DISEASE

EHA Library, Katarina Kovačević, 324710

SEVERE ANTITHROMBIN DEFICIENCY, HOMOZYGOUS ANTITHROMBIN BUDAPEST 3, CAUSES AGENESIS OF THE INFERIOR VENA CAVA SYSTEM.

EHA Library, Eugenia de la Morena, 324711

ASYMPTOMATIC DEEP VENOUS THROMBOSES ARE HIGHLY PREVALENT AMONG PROLONGED HOSPITALIZED SEVERE COVID-19 PATIENTS DESPITE THROMBOPROPHYLAXIS

EHA Library, Marko Lucijanic, 324712

GLIOBLASTOMA CELL POPULATIONS WITH DISTINCT ONCOGENIC PROGRAMS RELEASE PODOPLANIN AS PROCOAGULANT EXTRACELLULAR VESICLES

EHA Library, Nadim Tawil, 324713

THROMBOPHILIA AS RISK FACTOR FOR ASPARAGINASE RELATED VENOUS THROMBOEMBOLISM IN PEDIATRIC AND YOUNG ADULT PATIENTS AFFECTED BY ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Alessandra Serrao, 324714

THROLY SCORE SUCCESSFULLY CLASSIFIES HODGKIN LYMPHOMA PATIENTS AT RISK OF THROMBOEMBOLIC COMPLICATION

EHA Library, Darko Antic, 324715

FREQUENCY AND RISK FACTORS FOR THROMBOSIS IN ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY: A TWO CENTERS OBSERVATIONAL STUDY

EHA Library, Marco Cerrano, 324716

OUTCOME OF ELDERLY PATIENTS WITH VENOUS THROMBOEMBOLISM TREATED WITH DIRECT ORAL ANTICOAGULANTS - A RETROSPECTIVE COHORT STUDY

EHA Library, Irit Ayalon Dangur, 324717

INTEGRATION OF A MACHINE LEARNING-BASED MODEL INTO ROUTINE CYTOMORPHOLOGICAL DIAGNOSTICS: FIRST EXPERIENCES FROM THE BELUGA TRIAL

EHA Library, Christian Pohlkamp, 324718

ESTIMATED HOSPITALIZATION-RELATED COSTS WITH ORAL AZACITIDINE (ORAL-AZA) VS PLACEBO (PBO) FOR REMISSION MAINTENANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN SPAIN AND THE UNITED KINGDOM (UK)

EHA Library, Esther Natalie Oliva, 324719

SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE: 1-YEAR FOLLOW-UP INTERIM RESULTS FROM THE CARDINAL STUDY

EHA Library, Alexander Röth, 324720

PATIENT AND PHYSICIAN PREFERENCES FOR POST–HEMATOPOIETIC STEM CELL TRANSPLANTATION MAINTENANCE TREATMENT OF ACUTE MYELOID LEUKEMIA

EHA Library, Mo Zhou, 324721

THE BURDEN OF SICKLE CELL DISEASE (SCD) ON PATIENTS IN GHANA AND NIGERIA COMPARED WITH OTHER LOW-/MIDDLE-INCOME AND HIGH-INCOME COUNTRIES: RESULTS FROM THE SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)

EHA Library, Ifeyinwa Osunkwo, 324722

IMPACT OF EARLY RESPONSE ON OUTCOMES IN AL AMYLOIDOSIS FOLLOWING TREATMENT WITH FRONTLINE BORTEZOMIB

EHA Library, Sriram Ravichandran, 324723

RELATIONSHIP BETWEEN CORNEAL EXAM FINDINGS, BEST-CORRECTED VISUAL ACUITY (BCVA), AND OCULAR SYMPTOMS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING BELANTAMAB MAFODOTIN

EHA Library, evangelos Terpos, 324724

SELINEXOR CONTAINING REGIMENS IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH ANTI-CD38 MONOCLONAL ANTIBODIES

EHA Library, Cristina Gasparetto, 324725

INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN THE PHASE 2 CARTITUDE-2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Hermann Einsele, 324726

VACCINATION AGAINST SEASONAL INFLUENZA AND PNEUMONIA IMPROVES CLINICAL OUTCOME IN MULTIPLE MYELOMA PATIENTS RECEIVING CONTINUOUS TREATMENT WITH LENALIDOMIDE: A REAL-LIFE SURVEY

EHA Library, Anna Bulla, 324727

REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN MULTIPLE MYELOMA PATIENTS REFRACTORY TO LENALIDOMIDE

EHA Library, Xavier Leleu, 324728

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN EAST ASIAN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: IKEMA SUBGROUP ANALYSIS

EHA Library, Kihyun Kim, 324729

TUMOR CHARACTERISTICS OF DISEASE PROGRESSION AFTER BCMA-CART TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA WITH EXTRAMEDULLARY LESIONS

EHA Library, Yuelu Guo, 324730

ORAL SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (XPD) AT RECOMMENDED PHASE 2 DOSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

EHA Library, Darrell White, 324731

IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: UPDATED KARMMA RESULTS

EHA Library, Albert Oriol, 324732

ANALYSIS OF A PHASE 2 MINIMAL RESIDUAL DISEASE (MRD)-ADAPTIVE TRIAL OF ELOTUZUMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ELO-KRD) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)

EHA Library, Benjamin A Derman, 324733

REAL-WORLD DATA ON PATIENT CHARACTERISTICS AND TREATMENT PATTERNS FOR 3000 PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS IN EUROPE BETWEEN 2011 AND 2018: A RETROSPECTIVE STUDY BY THE EUROPEAN MYELOMA NETWORK

EHA Library, Efstathios Kastritis, 324734

ASSESSMENT OF TREATMENT RESPONSE BY MASS SPECTROMETRY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS FROM THE GEM2012MENOS65 CLINICAL TRIAL: COMPARISON WITH STANDARD SPEP/IFE

EHA Library, Noemi Puig, 324735

A META-ANALYSIS OF EFFICACY OF POMALIDOMIDE-BASED REGIMENS FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE EXPOSURE

EHA Library, Faith Davies, 324736

SAFETY AND EFFICACY OF DARATUMUMAB WITH IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH ONE PRIOR LENALIDOMIDE-BASED REGIMEN: THE DARIA STUDY

EHA Library, evangelos Terpos, 324737

EARLY INTENSIVE CONSOLIDATION WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN NEWLY DIAGNOSED HIGH-RISK MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

EHA Library, Samiksha Gupta, 324738

RESULTS ON EFFICACY AND SAFETY OF DARATUMUMAB WITH DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: THE DARE STUDY

EHA Library, Efstathios Kastritis, 324739

SAFETY AND TOLERABILITY OF CAEL-101 IN COMBINATION WITH CYCLOPHOSPHAMIDE-BORTEZOMIB-DEXAMETHASONE AND DARATUMUMAB IN PATIENTS WITH AL AMYLOIDOISIS

EHA Library, Jason Valent, 324740

SAFETY AND TOLERABILITY OF CAEL-101 IN PATIENTS WITH AL AMYLOIDOSIS IN A PHASE 2 STUDY FOR A MEDIAN OF 38 WEEKS

EHA Library, Jason Valent, 324741

POMALIDOMIDE, DEXAMETHASONE, AND DARATUMUMAB IN RELAPSED REFRACTORY MULTIPLE MYELOMA (MM-014 PHASE 2 TRIAL): A SUBANALYSIS OF PATIENTS PREVIOUSLY TREATED WITH LENALIDOMIDE AND A PROTEASOME INHIBITOR

EHA Library, Nizar J Bahlis, 324742

EARLY MORTALITY AMONG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE NETHERLANDS: A POPULATION-BASED STUDY

EHA Library, Mirian Brink, 324743

IMPACT OF T(11;14) ACCORDING TO INDUCTION REGIMEN IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS: LONG TERM FOLLOW-UP OF GEM05MENOS65 PETHEMA/GEM STUDY

EHA Library, David Moreno, 324744

RISK OF MULTIPLE MYELOMA AND OTHER MALIGNANCIES AMONG FIRST- AND SECOND-DEGREE RELATIVES; A POPULATION BASED STUDY OF10035 PATIENTS IN NORWAY WITH MULTIPLE MYELOMA

EHA Library, Øystein Langseth, 324745

BELANTAMAB MAFODOTIN TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY MYELOMA VIA GSK EXPANDED ACCESS PROGRAM: REAL-WORLD DATA

EHA Library, Tamir Shragai, 324746

PHASE 3 STUDY OF DARATUMUMAB, BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN ASIAN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): OCTANS

EHA Library, Jian Hou, 324747